BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, Pawlik TM. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 2014;120:3058-65. [PMID: 24917245 DOI: 10.1002/cncr.28843] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Pan J, Wang F, Ye L. Doxorubicin-induced epithelial–mesenchymal transition through SEMA 4A in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2016;479:610-4. [DOI: 10.1016/j.bbrc.2016.09.167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
2 Yates SG, Gavva C, Agrawal D, Sarode R. How do we transfuse blood components in cirrhotic patients undergoing gastrointestinal procedures?: TRANSFUSION IN CIRRHOSIS. Transfusion 2016;56:791-8. [DOI: 10.1111/trf.13495] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
3 Mohanty A, Fortune BE. Why Pursue a Fourth Year in Advanced/Transplant Hepatology? Dig Dis Sci 2016;61:1817-8. [PMID: 26971091 DOI: 10.1007/s10620-016-4108-3] [Reference Citation Analysis]
4 Ong HK, Tan WS, Ho KL. Virus like particles as a platform for cancer vaccine development. PeerJ 2017;5:e4053. [PMID: 29158984 DOI: 10.7717/peerj.4053] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
5 Burkhart RA, Ronnekleiv-Kelly SM, Pawlik TM. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. Surg Oncol. 2017;26:138-145. [PMID: 28577719 DOI: 10.1016/j.suronc.2017.01.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
6 Kurtz CB, Millet YA, Puurunen MK, Perreault M, Charbonneau MR, Isabella VM, Kotula JW, Antipov E, Dagon Y, Denney WS, Wagner DA, West KA, Degar AJ, Brennan AM, Miller PF. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci Transl Med 2019;11:eaau7975. [PMID: 30651324 DOI: 10.1126/scitranslmed.aau7975] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 45.5] [Reference Citation Analysis]
7 Sun Y, Chang J, Liu X, Liu C. Mortality trends of liver diseases in mainland China over three decades: an age-period-cohort analysis. BMJ Open 2019;9:e029793. [PMID: 31712333 DOI: 10.1136/bmjopen-2019-029793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Burkhart RA, Pawlik TM. Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729235. [PMID: 28975828 DOI: 10.1177/1073274817729235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
9 Chen X, Zhang S, Wang Z, Wang F, Cao X, Wu Q, Zhao C, Ma H, Ye F, Wang H, Fang Z. Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway. J Exp Clin Cancer Res 2018;37:128. [PMID: 29954442 DOI: 10.1186/s13046-018-0787-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
10 Lan J, Wang N, Huang L, Liu Y, Ma X, Lou H, Chen C, Feng Y, Pan W. Design and synthesis of novel tetrandrine derivatives as potential anti-tumor agents against human hepatocellular carcinoma. European Journal of Medicinal Chemistry 2017;127:554-66. [DOI: 10.1016/j.ejmech.2017.01.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
11 Ji D, Chen GF, Wang JC, Ji SH, Wu XW, Lu XJ, Chen JL, Li JT. Hsa_circ_0070963 inhibits liver fibrosis via regulation of miR-223-3p and LEMD3. Aging (Albany NY) 2020;12:1643-55. [PMID: 32003753 DOI: 10.18632/aging.102705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Li C, Tan YH, Sun J, Deng FM, Liu YL. PAX6 contributes to the activation and proliferation of hepatic stellate cells via activating Hedgehog/GLI1 pathway. Biochem Biophys Res Commun 2020;526:314-20. [PMID: 32209258 DOI: 10.1016/j.bbrc.2020.03.086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 de la Torre AN, Contractor S, Castaneda I, Cathcart CS, Razdan D, Klyde D, Kisza P, Gonzales SF, Salazar AM. A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect. J Hepatocell Carcinoma 2017;4:111-21. [PMID: 28848723 DOI: 10.2147/JHC.S136652] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
14 Kim J, Hyun J, Wang S, Lee C, Lee JW, Moon EY, Cha H, Diehl AM, Jung Y. Thymosin beta-4 regulates activation of hepatic stellate cells via hedgehog signaling. Sci Rep 2017;7:3815. [PMID: 28630423 DOI: 10.1038/s41598-017-03782-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
15 Clark PJ, Stuart KA, Leggett BA, Crawford DH, Boyd P, Fawcett J, Whiteman DC, Baade PD. Remoteness, race and social disadvantage: disparities in hepatocellular carcinoma incidence and survival in Queensland, Australia. Liver Int 2015;35:2584-94. [PMID: 25900432 DOI: 10.1111/liv.12853] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
16 Pontoriero AC, Trinks J, Hulaniuk ML, Caputo M, Fortuny L, Pratx LB, Frías A, Torres O, Nuñez F, Gadano A, Argibay P, Corach D, Flichman D. Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations. BMC Genet 2015;16:93. [PMID: 26219465 DOI: 10.1186/s12863-015-0255-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
17 Chen VC, Lin CF, Hsieh YH, Liang HY, Huang KY, Chiu WC, Lee Y, McIntyre RS, Chan HL. Hepatocellular carcinoma and antidepressants: a nationwide population-based study. Oncotarget 2017;8:30464-70. [PMID: 27783998 DOI: 10.18632/oncotarget.12826] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
18 Ullah A, Chen G, Hussain A, Khan H, Abbas A, Zhou Z, Shafiq M, Ahmad S, Ali U, Usman M, Raza F, Ahmed A, Qiu Z, Zheng M, Liu D. Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis. Int J Nanomedicine 2021;16:4451-70. [PMID: 34234436 DOI: 10.2147/IJN.S314367] [Reference Citation Analysis]
19 Desai AP, Reau N. The Burden of Rehospitalization for Patients With Liver Cirrhosis. Hosp Pract (1995) 2016;44:60-9. [PMID: 26782133 DOI: 10.1080/21548331.2016.1142828] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
20 Jing F, Geng Y, Xu XY, Xu HY, Shi JS, Xu ZH. MicroRNA29a Reverts the Activated Hepatic Stellate Cells in the Regression of Hepatic Fibrosis through Regulation of ATPase H⁺ Transporting V1 Subunit C1. Int J Mol Sci 2019;20:E796. [PMID: 30781750 DOI: 10.3390/ijms20040796] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Hirode G, Vittinghoff E, Wong RJ. Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample. Dig Dis Sci 2019;64:1448-57. [PMID: 30863953 DOI: 10.1007/s10620-019-05576-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
22 Lu C, White SJ, Ye IB, Mikhail CM, Cheung ZB, Cho SK. The Effects of Liver Disease on Surgical Outcomes Following Adult Spinal Deformity Surgery. World Neurosurg 2019;130:e498-504. [PMID: 31254688 DOI: 10.1016/j.wneu.2019.06.137] [Reference Citation Analysis]
23 Abbasi U, Abbina S, Gill A, Takuechi LE, Kizhakkedathu JN. Role of Iron in the Molecular Pathogenesis of Diseases and Therapeutic Opportunities. ACS Chem Biol 2021;16:945-72. [PMID: 34102834 DOI: 10.1021/acschembio.1c00122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Polednak AP. Surveillance of US Death Rates from Chronic Diseases Related to Excessive Alcohol Use. Alcohol Alcohol 2016;51:54-62. [PMID: 26041609 DOI: 10.1093/alcalc/agv056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
25 Yu F, Geng W, Dong P, Huang Z, Zheng J. LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212. Cell Death Dis 2018;9:1014. [PMID: 30282972 DOI: 10.1038/s41419-018-1068-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
26 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology 2019;70:531-44. [DOI: 10.1016/j.jhep.2018.10.033] [Cited by in Crossref: 452] [Cited by in F6Publishing: 433] [Article Influence: 150.7] [Reference Citation Analysis]
27 Xuan J, Huang A, Hu D, Geng J, Tian Y, Cheng Z, Qiu Y. Huagan tongluo Fang improves liver fibrosis via down-regulating miR-184 and up-regulating FOXO1 to inhibit Th17 cell differentiation. Exp Mol Pathol 2020;115:104447. [PMID: 32380055 DOI: 10.1016/j.yexmp.2020.104447] [Reference Citation Analysis]
28 Ho MC, Hasegawa K, Chen XP, Nagano H, Lee YJ, Chau GY, Zhou J, Wang CC, Choi YR, Poon RT, Kokudo N. Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer 2016;5:245-56. [PMID: 27781197 DOI: 10.1159/000449336] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
29 Elsaid MI, Rustgi VK, Loo N, Aggarwal K, Li-mcleod J, Niu X, Poordad F. The burden associated with thrombocytopenia and platelet transfusions among patients with chronic liver disease. Journal of Medical Economics 2020;23:378-85. [DOI: 10.1080/13696998.2019.1699563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Van Dyke AL, Shiels MS, Jones GS, Pfeiffer RM, Petrick JL, Beebe-Dimmer JL, Koshiol J. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. Cancer 2019;125:1489-98. [PMID: 30645774 DOI: 10.1002/cncr.31942] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
31 Farrell C, Halpen A, Cross TJ, Richardson PD, Johnson P, Joekes EC. Ultrasound surveillance for hepatocellular carcinoma: service evaluation of a radiology-led recall system in a tertiary-referral centre for liver diseases in the UK. Clin Radiol. 2017;72:338.e11-338.e17. [PMID: 28041651 DOI: 10.1016/j.crad.2016.10.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
32 Yao Y, Zhang W, Ming R, Deng Q, Zuo A, Zhang S, Ying Y, Zhao Y, Ma J. Noninvasive 40-Hz Light Flicker Rescues Circadian Behavior and Abnormal Lipid Metabolism Induced by Acute Ethanol Exposure via Improving SIRT1 and the Circadian Clock in the Liver-Brain Axis. Front Pharmacol 2020;11:355. [PMID: 32269528 DOI: 10.3389/fphar.2020.00355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
33 Tomedi LE, Roeber J, Landen M. Alcohol Consumption and Chronic Liver Disease Mortality in New Mexico and the United States, 1999-2013. Public Health Rep 2018;133:287-93. [PMID: 29664698 DOI: 10.1177/0033354918766890] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Saleh M, Virarkar M, Bura V, Valenzuela R, Javadi S, Szklaruk J, Bhosale P. Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings. Abdom Radiol (NY) 2020;45:3662-80. [PMID: 32417933 DOI: 10.1007/s00261-020-02559-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Milic S, Mikolasevic I, Orlic L, Devcic E, Starcevic-Cizmarevic N, Stimac D, Kapovic M, Ristic S. The Role of Iron and Iron Overload in Chronic Liver Disease. Med Sci Monit. 2016;22:2144-2151. [PMID: 27332079 DOI: 10.12659/msm.896494] [Cited by in Crossref: 60] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
36 Cao C, Li J, Li G, Hu G, Deng Z, Huang B, Yang J, Li J, Cao S. Long Non-coding RNA TMEM220-AS1 Suppressed Hepatocellular Carcinoma by Regulating the miR-484/MAGI1 Axis as a Competing Endogenous RNA. Front Cell Dev Biol 2021;9:681529. [PMID: 34422806 DOI: 10.3389/fcell.2021.681529] [Reference Citation Analysis]
37 Hyun J, Wang S, Kim J, Rao KM, Park SY, Chung I, Ha CS, Kim SW, Yun YH, Jung Y. MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression. Nat Commun 2016;7:10993. [PMID: 27001906 DOI: 10.1038/ncomms10993] [Cited by in Crossref: 120] [Cited by in F6Publishing: 120] [Article Influence: 20.0] [Reference Citation Analysis]
38 Guo Z, Li D, Peng H, Kang J, Jiang X, Xie X, Sun D, Jiang H. Specific hepatic stellate cell-penetrating peptide targeted delivery of a KLA peptide reduces collagen accumulation by inducing apoptosis. J Drug Target 2017;25:715-23. [PMID: 28447897 DOI: 10.1080/1061186X.2017.1322598] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
39 Wild SH, Morling JR, McAllister DA, Kerssens J, Fischbacher C, Parkes J, Roderick PJ, Sattar N, Byrne CD. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. J Hepatol. 2016;64:1358-1364. [PMID: 26812073 DOI: 10.1016/j.jhep.2016.01.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]